Case Report| Volume 32, ISSUE 6, P648-650, December 2019

Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome



      Most patients with phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA)-related overgrowth spectrum become symptomatic early in life and need treatment before puberty. Recently, the specific inhibition of PIK3CA pathways has been proposed as a therapeutic option for these patients improving their surgical options and quality of life. Alpelisib, a specific alpha fraction inhibitor, has shown promising results.


      A 17-year-old girl presented with severe involvement of her external genitalia with a combined vascular malformation in the context of congenital, lipomatous, overgrowth, vascular malformations, epidermal nevi and spinal/skeletal anomalies and/or scoliosis syndrome, needing frequent blood transfusions for anemia due to vaginal bleeding and use of a crutch for walking. After failure of treatment with rapamycin, compassionate treatment with alpelisib was started with excellent response.

      Summary and Conclusion

      PIK3CA inhibitors might become a new option of treatment for PIK3CA-related overgrowth spectrum patients.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Keppler-Noreuil K.M.
        • Sapp J.C.
        • Lindhurst M.J.
        • et al.
        Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
        Am J Med Genet. 2014; 164: 1713
        • Kurek K.C.
        • Luks V.L.
        • Ayturk U.M.
        • et al.
        Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.
        Am J Hum Genet. 2012; 90: 1108
        • Venot Q.
        • Blanc T.
        • Rabia S.H.
        • et al.
        Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
        Nature. 2018; 558: 540
        • Keppler-Noreuil K.M.
        • Rios J.J.
        • Parker V.E.
        • et al.
        PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
        Am J Med Genet A. 2015; 167A: 287
        • Triana P.
        • Dore M.
        • Cerezo V.N.
        • et al.
        Sirolimus in the treatment of vascular anomalies.
        Eur J Pediatr Surg. 2017; 27: 86
        • Engelman J.A.
        Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
        Nat Rev Cancer. 2009; 9: 550
        • Juric D.
        • Rodon J.
        • Tabernero J.
        • et al.
        Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study.
        J Clin Oncol. 2018; 36: 1291
        • Juric D.
        • Janku F.
        • Rodón J.
        • et al.
        Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial.
        JAMA Oncol. 2018; 5: e184475
        • Mayer I.A.
        • Abramson V.G.
        • Formisano L.
        • et al.
        A phase Ib study of alpelisib (BYL719), a PI3Kα-specific inhibitor, with letrozole in ER+/HER2− metastatic breast cancer.
        Clin Cancer Res. 2017; 23: 26